BIOARDIS
BioArdis provides their services on value creation through efficient small molecule drug discovery; perfecting the process from lead to preclinical development candidate. They are motivated by science, so they are not focused on any particular therapeutic area. Through top-tier executive and advisory teams, they develop a pipeline of internal and partnered programs with the goal of delivering PDCs in timeframes and at costs not achieved previously. Through critical relationships with preferred research partners, they will continue to expand their pipeline to routinely deliver both first-in-class and best-in-class products.
BIOARDIS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.bioardis.com
Status:
Active
Contact:
+1 858 412 2027
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Domain Not Resolving
Current Employees Featured
Founder
Official Site Inspections
http://www.bioardis.com
- Host name: 191.0.153.160.host.secureserver.net
- IP address: 160.153.0.191
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "BioArdis"
About Us - BioArdis
BioArdis launched its cell therapy platform with a mission to develop first-in-class CAR-T therapies that target solid tumors with a high degree of precision, safety and efficacy. BioArdis is powered by a proprietary, accelerated high …See details»
BioArdis - Crunchbase Company Profile & Funding
BioArdis provides their services on value creation through efficient small molecule drug discovery; perfecting the process from lead to preclinical development …See details»
BioArdis 2025 Company Profile: Valuation, Funding
BioArdis General Information Description. Operator of a pre-clinical biopharmaceutical development company intended to provide validated …See details»
BioArdis - LinkedIn
BioArdis is an innovative therapeutic development company with a pipeline of oncology and immuno-oncology drug candidates, and a novel chimeric antigen receptor T cell (“CAR-T”) …See details»
Our Portfolio - BioArdis
BioArdis’s CAR-T platform is powered by a proprietary and highly differentiated large-scale screening engine that begins with target tumor antigen selection and optimizes key elements of a CAR to specifically target selected tumor antigen. …See details»
BioArdis Company Profile | Management and Employees List
BioArdis is an innovative therapeutic development company specializing in oncology and immuno-oncology drug candidates. The company has a novel chimeric antigen receptor T cell (CAR-T) …See details»
BioArdis - Overview, News & Similar companies | ZoomInfo.com
Apr 2, 2020 BioArdis LLC, founded in 2017 with operations in San Diego and Shanghai, is a biopharmaceutical company that strives to discover and develop life-c hanging medicines for …See details»
BioArdis - VentureRadar
" BioArdis is an innovative therapeutic development company with a pipeline of oncology and immuno-oncology drug candidates, and a novel chimeric antigen receptor T cell (“CAR-T”) …See details»
BioArdis - Company Profile - Tracxn
Jan 17, 2025 BioArdis is a funded company. Who are BioArdis's investors? BioArdis has 1 institutional investor - BridgeWest Group. View details of BioArdis funding rounds and …See details»
BioArdis (Jiangsu) Limited - Drug pipelines, Patents, Clinical trials ...
Explore BioArdis (Jiangsu) Limited with its drug pipeline, therapeutic area, technology platform, .See details»
BioArdis - Portfolio Company Profile, Executives and Private Equity …
BioArdis is a pre-clinical investment and biotechnology company focused on value creation through efficient small molecule drug discovery. See BioArdis's complete profile, including its …See details»
BioArdis - Products, Competitors, Financials, Employees, …
BioArdis is an innovative therapeutic development company focused on oncology and immuno-oncology drug candidates. Use the CB Insights Platform to explore BioArdis's full profile. …See details»
BioArdis LLC - Drug pipelines, Patents, Clinical trials - Synapse
Explore BioArdis LLC with its drug pipeline, therapeutic area, technology platform, 2 news, Disease Domain:Neoplasms, Technology Platform:Autologous CAR-T, CAR-T ...See details»
BioArdis names Kedar Muley Chief Business Officer, acting CEO
May 4, 2021 "BioArdis has been very proficient in developing a deep pipeline of best-in-class small molecule therapies and a cell therapy discovery engine that has generated multiple …See details»
Delving into the Latest Updates on BioArdis LLC with Synapse
了解BioArdis LLC (BioArdis LLC)公司的药物管线，治疗领域，技术平台，以及它的2篇新闻，疾病领域:肿瘤，技术平台:自体CAR-T，CAR-T，小分子化药，药物:MRGPRX2 …See details»
BioArdis DMF, CEP, Written Confirmations, FDF, Prices, Patents, …
BioArdis, LLC is a pre-clinical investment and biotechnology company focused on value creation through efficient small molecule drug discovery; perfecting the process from Lead through …See details»
Shenogen enters into an Exclusive License with BioArdis to …
Shenogen, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients …See details»
BioArdis and Shenogen to develop commercialize novel FGFR4
BioArdis will retain all rights to the licensed product in the rest of the world. BIO-1262 is being evaluated as a potential new treatment for hepatocellular carcinoma (HCC) and other solid …See details»
Shenogen enters into an Exclusive License with BioArdis to …
Apr 3, 2020 BioArdis LLC, founded in 2017 with operations in San Diego and Shanghai, is a biopharmaceutical company that strives to discover and develop life-changing medicines for …See details»
Inside the futuristic biotech startup Cellares that’s building a cure ...
1 day ago Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in fundingSee details»